tert-butyl (5-methylhex-1-en-3-yl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (5-methylhex-1-en-3-yl)carbamate
• 英文别名: 3-t-Butyloxycarbonylamino-5-methylhex-1-ene；tert-butyl N-(5-methylhex-1-en-3-yl)carbamate
• 化学式: C₁₂H₂₃NO₂
• 分子量: 213.32
• InChiKey: OOYLKAHPLMLJPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  2-甲基-2-丙基[(2S)-4-甲基-1-氧代-2-戊烷基]氨基甲酸酯	tert-butoxycarbonyl-L-leucinal	58521-45-2	C11H21NO3	215.293

反应信息

• 作为反应物：
  描述：

  tert-butyl (5-methylhex-1-en-3-yl)carbamate 在 甲醇 、 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 N-(4-methoxybenzyl)-5-methylhex-1-en-3-amine
  参考文献：
  名称：

  电子贫化环丙烷的羰基化C-C键活化：铑催化的（3 + 1 + 2）环丙基酰胺的环加成反应

  摘要：

  环丙基酰胺的Rh催化的羰基C-C键活化生成结构稳定的Rhodacyclopentanones，其与（3 + 1 + 2）环加成中的链状烯烃结合。这些研究提供了多组分环加成反应的第一个例子，该过程通过“简单的”电子贫乏的环丙烷的C-C键活化而进行。

  DOI：

  10.1002/anie.201811460
• 作为产物：
  描述：

  2-甲基-2-丙基[(2S)-4-甲基-1-氧代-2-戊烷基]氨基甲酸酯 生成 tert-butyl (5-methylhex-1-en-3-yl)carbamate
  参考文献：
  名称：

  LULY, JAY R.;PLATTNER, JOHN J.;DELLARIA, JOSEPH F.

  摘要：

  DOI：

文献信息

• Angiotensinogen analogs
  申请人：Abbott Laboratories

  公开号：US04857507A1

  公开（公告）日：1989-08-15

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R.sub.1 is phenoxy, thiophenoxy or anilino, B is CH.sub.2 or CHOH or A is hydrogen, R.sub.3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R.sub.5 is loweralkyl, cycloalkylmethyl or benzyl; R.sub.2 and R.sub.4 are independently selected from hydrogen and loweralkyl; R.sub.6 is CHOH or CO; R.sub.7 is CH.sub.2, CF.sub.2 or CF with the proviso that when R.sub.6 is CO, R.sub.7 is CF.sub.2 ; R.sub.8 is CH.sub.2, CHR.sub.14 wherein R.sub.14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R.sub.7 and R.sub.8 taken together can be ##STR3## with the proviso that when R.sub.7 is CF.sub.2, R.sub.8 is CH.sub.2 ; E is O, S, SO, SO.sub.2, NR.sub.15 wherein R.sub.15 is hydrogen or loweralkyl or NR.sub.16 CO wherein R.sub.16 is hydrogen or loweralkyl; R.sub.9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R.sub.9 taken together can be N.sub.3, with the proviso that when E is NH, R.sub.9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

  该发明涉及以下结构的肾素抑制化合物##STR1##其中A为氢；较低烷基；芳基烷基；OR.sub.10或SR.sub.10，其中R.sub.10为氢，较低烷基或氨基烷基；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别选择自氢，较低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.13为较低烷基，环烷基，芳基，芳基烷基，烷氧基，烯基氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，(羟基烷基)(烷基)氨基，(二羟基烷基)(烷基)氨基，氨基烷基，烷氧羰基烷基，羧基烷基，N-保护氨基烷基，烷基氨基烷基，(N-保护)(烷基)氨基烷基，二烷基氨基烷基，(杂环)烷基或取代或未取代的杂环；W为CO或CHOH，U为CH.sub.2或NR.sub.2，但当W为CHOH时，U为CH.sub.2；R.sub.1为较低烷基，环烷基甲基，苄基，.alpha.，.alpha.-二甲基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，B为CH.sub.2或CHOH或A为氢，R.sub.3为较低烷基，烯基较低烷基，苄基或杂环环取代甲基，R.sub.5为较低烷基，环烷基甲基或苄基；R.sub.2和R.sub.4分别选择自氢和较低烷基；R.sub.6为CHOH或CO；R.sub.7为CH.sub.2，CF.sub.2或CF，但当R.sub.6为CO时，R.sub.7为CF.sub.2；R.sub.8为CH.sub.2，CHR.sub.14，其中R.sub.14为较低烷基，环烷基，环烷基烷基，芳基或芳基烷基，或R.sub.7和R.sub.8一起可以是##STR3##但当R.sub.7为CF.sub.2时，R.sub.8为CH.sub.2；E为O，S，SO，SO.sub.2，NR.sub.15，其中R.sub.15为氢或较低烷基或NR.sub.16 CO，其中R.sub.16为氢或较低烷基；R.sub.9为较低烷基，环烷基，环烷基烷基，芳基，芳基烷基或N-保护基，或E和R.sub.9一起可以是N.sub.3，但当E为NH时，R.sub.9为N-保护基；及其药学上可接受的盐。
• Glaucoma treatment
  申请人：Abbott Laboratories

  公开号：US04927807A1

  公开（公告）日：1990-05-22

  A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: ##STR1## wherein A is a substituent; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 wherein R.sub.2 is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino; R.sub.3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R.sub.4 is a substituted amino group; or pharmaceutically acceptable salts or esters thereof. Also disclosed are compositions, methods and kits for treating glaucoma or reducing and/or controlling intraocular pressure wherein the renin inhibiting compound is administered in combination with a beta-adrenergic antagonist, a steroidal antiinflammatory agent or an angiotensin converting enzyme inhibiting compound.

  一种用于治疗或减少和/或控制眼内压的方法和组合物，包括给予有效量的下式化合物的抑制肾素的化合物：##STR1## 其中A是取代基；W是CO或CHOH，U是CH.sub.2或NR.sub.2，其中R.sub.2是氢或较低烷基；但当W是CHOH时，则U为CH.sub.2；R.sub.1是较低烷基，环烷基，苄基，(α，α)-二甲基苄基，4-羟基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)甲基，苯乙基，1-苄氧基乙基，苯氧基，噻吩氧基或苯胺基；R.sub.3是较低烷基，较低烯基，((烷氧基)烷氧基)烷基，羧基烷基，(硫代烷氧基)烷基，苄基或杂环戒取代甲基；R.sub.4是取代氨基；或其药学上可接受的盐或酯。还公开了用于治疗青光眼或减少和/或控制眼内压的组合物、方法和试剂盒，其中抑制肾素的化合物与β-肾上腺素受体拮抗剂、类固醇抗炎药或抑制血管紧张素转换酶的化合物结合给予。
• Renin inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US04645759A1

  公开（公告）日：1987-02-24

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is an N-protecting group; n is 0 or 1; B is hydrogen, hydroxy, NH, loweralkyl or arylalkyl; with the proviso that when A is an N-protecting group, B is NH and when n is 0, B is hydrogen, hydroxy, loweralkyl or arylalkyl; R.sub.1, R.sub.3 and R.sub.5 are loweralkyl or hydrophilic, lipophilic or aromatic amino acid side chains and may be the same or different; R.sub.2, R.sub.4, R.sub.7, R.sub.8 and R.sub.9 are hydrogen or loweralkyl and may be the same or different; X is NH, O, S, SO or SO.sub.2 ; and R.sub.6 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protecting group, with the proviso that R.sub.6 may be an N-protecting group when X is NH.

  该发明涉及一种抑制肾素的化合物，其化学式为##STR1##其中A是N-保护基团；n为0或1；B是氢、羟基、NH、低碳烷基或芳基烷基；但当A是N-保护基团时，B为NH，且当n为0时，B为氢、羟基、低碳烷基或芳基烷基；R.sub.1、R.sub.3和R.sub.5为低碳烷基或亲水性、疏水性或芳香族氨基酸侧链，可以相同也可以不同；R.sub.2、R.sub.4、R.sub.7、R.sub.8和R.sub.9为氢或低碳烷基，可以相同也可以不同；X为NH、O、S、SO或SO.sub.2；R.sub.6为低碳烷基、环烷基、环烷基烷基、芳基、芳基烷基或N-保护基团，但当X为NH时，R.sub.6可以是N-保护基团。
• Retroisostere Dipeptide, Verfahren zu ihrer Herstellung und ihre Verwendung als Renininhibitoren in Arzneimitteln
  申请人：BAYER AG

  公开号：EP0441191A2

  公开（公告）日：1991-08-14

  Die Erfindung betrifft neue retroisostere Dipeptide der allgemeinen Formel I in welcher X, A, B, D, L, M, Y, R₁ und R₂ die in der Beschreibung angegebene Bedeutung haben, Verfahren zu ihrer Herstellung und ihre Verwendung als Renininhibitoren in Arzneimitteln, insbesondere in kreislaufbeeinflussenden Arzneimitteln.

  本发明涉及通式 I 的新型反式二肽 中 X、A、B、D、L、M、Y、R₁ 和 R₂ 的含义、其制备工艺及其在药物中作为肾素抑制剂的用途，特别是在循环影响药物中的用途。
• COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES
  申请人：American Life Science Pharmaceuticals, Inc.

  公开号：EP3296295A1

  公开（公告）日：2018-03-21

  In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin.; In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g., AD, VD, CDS. The invention also provides alternative dosage forms and formulations for AB-007 and loxistatin, and for compounds of this invention, which can be used e.g., to treat AD, VD and CDS, in humans and in non-human animals.

  在另一个实施方案中，本发明提供了用于改善具有β-淀粉样蛋白成分的疾病和病症的组合物和方法，包括阿尔茨海默病（AD）、血管性痴呆（VD）、痴呆、痴呆前期、认知功能障碍综合征（CDS）以及人类和非人类动物的认知能力丧失。在另一个实施方案中，本发明提供了AB-007及其酸形式E64c（loxistatin）的类似物、它们的制备及其药物组合物以及制造和使用方法。在另一个实施方案中，本发明的组合物是AB-007（或E64d）和E64c（或loxistatin）的氚代类似物。在可选的实施方案中，本发明的组合物与AB-007和loxistatin相比是代谢受阻的形式；在可选的实施方案中，本发明的组合物用于改善（包括治疗、减缓、逆转或预防）可通过部分或完全抑制半胱氨酸蛋白酶（如AD、VD、CDS）来改善的疾病或病症。本发明还提供了AB-007和loxistatin以及本发明化合物的替代剂型和制剂，可用于治疗人类和非人类动物的AD、VD和CDS等。